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Eye on the B-ALL: B-cell receptor repertoires reveal
persistence of numerous B-lymphoblastic leukemia
subclones from diagnosis to relapse
RJM Bashford-Rogers1,2,9, KA Nicolaou3,9, J Bartram4,5, NJ Goulden4, L Loizou6, L Koumas3, J Chi3, M Hubank5, P Kellam1,7,
PA Costeas3 and GS Vassiliou1,3,8
The strongest predictor of relapse in B-cell acute lymphoblastic leukemia (B-ALL) is the level of persistence of tumor cells after initial
therapy. The high mutation rate of the B-cell receptor (BCR) locus allows high-resolution tracking of the architecture, evolution and
clonal dynamics of B-ALL. Using longitudinal BCR repertoire sequencing, we ﬁnd that the BCR undergoes an unexpectedly high
level of clonal diversiﬁcation in B-ALL cells through both somatic hypermutation and secondary rearrangements, which can be used
for tracking the subclonal composition of the disease and detect minimal residual disease with unprecedented sensitivity. We go on
to investigate clonal dynamics of B-ALL using BCR phylogenetic analyses of paired diagnosis-relapse samples and ﬁnd that large
numbers of small leukemic subclones present at diagnosis re-emerge at relapse alongside a dominant clone. Our ﬁndings suggest
that in all informative relapsed patients, the survival of large numbers of clonogenic cells beyond initial chemotherapy is a
surrogate for inherent partial chemoresistance or inadequate therapy, providing an increased opportunity for subsequent
emergence of fully resistant clones. These results frame early cytoreduction as an important determinant of long-term outcome.
Leukemia (2016) 30, 2312–2321; doi:10.1038/leu.2016.142
INTRODUCTION
Advances in the treatment of B-cell acute lymphoblastic leukemia
(B-ALL) have increased long-term survival of pediatric patients to
above 80%, although the equivalent rate for adults remains poor
at 30–40%,1,2 with relapse representing the leading cause of
mortality at all ages. B-ALL is thought to arise from the leukemic
transformation of a lymphoid precursor at an early stage of B-cell
differentiation. B-cells express distinct cell-surface B-cell receptors
(BCRs), generated during B-cell differentiation through the rearran-
gement and assembly of heavy- and light-chain gene variable (V),
diverse (D) and joining (J) elements into V(D)J segments through V
(D)J recombination.3 BCRs represent unique markers for each B-cell
clone, where the accumulation of BCR mutational variants have been
reported to occur at signiﬁcantly greater rates than that of the rest of
the genome,4–6 making this genomic region ideal for characterization
of B-cell population dynamics by high-throughput sequencing.7,8 The
BCR sequence repertoire of an individual thus represents a snapshot of
their B-cell population structure and can identify the presence of clonal
proliferations, making it useful in the diagnosis and monitoring of
B-cell malignancies.9 Next-generation sequencing of BCR repertoires10
can therefore facilitate the longitudinal study of the clonal dynamics of
malignant B-cell populations from diagnosis to relapse.
The early clonal dynamics of ALL during treatment are highly
predictive of relapse11–13 as is the detection of minimal residual
disease (MRD) at later stages14 in both children and adults,7,15,16
with most reported cases of B-ALL relapse associated with the
acquisition of drug resistance mutations. Here, we develop a robust
protocol for high-throughput sequencing and analysis of BCR
sequence repertoires in B-ALL and demonstrate that it has equal or
superior sensitivity and speciﬁcity for MRD detection compared with
fusion gene qRT-PCR, when applied to the same RNA material used
for the latter. We then use our platform to study DNA samples in
the same way in order to (a) decipher the clonal architecture of
serial patient samples taken at diagnosis, during treatment and,
where applicable, at relapse and (b) characterize the population
dynamics between paired diagnosis and MRD-positive samples.
We ﬁnd multiple related malignant clone clusters, many of which
persist from diagnosis to relapse, indicating partial chemoresis-
tance and/or inadequate therapy in those who go on to relapse.
Our ﬁndings support the premise that despite signiﬁcant
reductions in the number of bulk B-ALL cells with initial therapy,
primary partial chemoresistance affords clonogenic leukemic
cells with the opportunity to acquire additional bona ﬁde
resistance mutations culminating to relapse.
MATERIALS AND METHODS
Samples
Total nucleated bone marrow (BM) cells were isolated from aspirate
samples after erythrocyte lysis and peripheral blood (PB) mononuclear cells
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from 10ml of blood after Ficoll and erythrocyte lysis. Total RNA was isolated
and puriﬁed using QIAamp DNA/RNA blood mini-kit and QIAcube
Automated Robotic System (Qiagen, Manchester, UK). Samples were derived
from (i) patients with archived samples, which were studied using
informative qRT-PCR for fusion genes and (ii) patients who went on to
relapse after achieving remission.
BCR ampliﬁcation, sequencing and assembly
RT-PCR and PCRs were performed as described previously8 using FR1
primer(s). MiSeq libraries were generated and reads ﬁltered as described
previously (detail in Supplementary information).10 The network genera-
tion algorithm and network properties were calculated as in Bashford-
Rogers et al.:8 each vertex represents a unique sequence, where relative
vertex size is proportional to the number of identical reads. Edges join
vertices that differ by single nucleotide non-indel differences and clusters
are collections of related, connected vertices. Alignments were performed
using Mafft17 and maximum parsimony trees ﬁtted using Paup* version 4
using the best-ﬁt nucleotide substitution model in MODELTEST.18,19
Aligned sequences were then analyzed using a new computational
pipeline, MRD Assessment and Retrieval Code in pYthon (MRDARCY), to
identify all clusters ⩾2.5% in index samples, and to subsequently mine all
sequences with ⩽ 8 bp mismatches from the clusters in all samples
associated with the corresponding patient.
Secondary rearrangement analysis
BCRs represented by 42 reads from all clusters greater than 2.5% of the
total repertoire for each patient were captured and their stem regions
identiﬁed (deﬁned as N-IgHD-N-IgHJ regions starting 3bp downstream of
the IgHV gene boundary). All BCRs containing these stem regions were
captured at each time point or searched-for in unrelated healthy controls.
Stem regions were clustered together by similarity (where all stem regions
within a cluster are related to at least one other member by a single bp
difference) and the relative frequencies of each IgHV gene, represented by
sequences containing the stem sequence group, were determined by
BLAST20 using the IMGT reference gene database.
qPCR, blast quantiﬁcation and cytogenetics
qPCR for fusion genes was performed as in Gabert et al.21 Blast counts were
assessed from BM or PB (Supplementary Table S1) as a percentage of total
nucleated cells by morphology.22 Complete remission was deﬁned as BM
blasts o5%. Day 28 MRD was performed by RT-PCR.23 Interphase nuclei
were screened by ﬂuorescence in situ hybridization to assess abnormal
cytogenetics at diagnosis and relapse.24
Mutational proﬁle and PCR/sequencing error analysis
To test the signiﬁcance of the overlap between diagnosis and relapse
samples, where the null hypothesis assumed that the most frequently
observed BCR sequences (the central BCRs in each tree) are the only BCRs
retained throughout therapy and represent the progenitor cell(s) of all
relapsed B-ALL cells. If the BCR sequence length is l, the nucleotide distance
from the central BCR d and any position can mutate to any of three other
bases, then the number of potential mutational combinations is:
Number of combinations of mutations ¼ l!
l - dð Þ!d!
 
3d
The hypergeometric test in R was used to calculate the probability of
observing equal or greater BCR sequence overlap between diagnosis and
relapse by chance for all pairs tested from each aligned B-ALL BCR sequence
cluster. The same analyses were performed on the data sets for control
genes (human GAPDH/β-globin from healthy donors in Bashford-Rogers
et al.8). The 'true' control gene sequence within each control sample was
deﬁned as the highest observed sequence in the sample, where sequence
variants from these were deﬁned as PCR/sequencing errors. The probabilities
of random overlap between the sites of PCR/sequencing error were
calculated using the hypergeometric distribution (probability for observed
or greater overlap to occur by chance) (Supplementary Figure S7).
To account for any potential sequencing/PCR mutational biases, the
baseline observed probabilities of overlap between mutations in indepen-
dent V-(D)-J recombination events were used to compare the diagnosis-
relapse samples: for all the healthy control samples, we identiﬁed all
sequences within clusters of more than six sequences, and mutations within
the V genes were determined. By comparing the occurrence of each V gene
mutation between independent clones (deﬁned as either clones sharing the
same V gene allele but a different J gene or same V gene allele in dependent
healthy individuals), the baseline frequency of shared mutations was
calculated. Similarly, the mutations away from the central BCR in the B-ALL
clone between diagnosis and relapse samples from each relapsing patient
were determined, and the distribution of overlapping mutational sites was
determined. The difference in frequency of overlapping mutations between
the healthy V gene independent mutations and the diagnosis-relapse
mutations was statistically tested using the Mann–Whitney test (one-sided).
RESULTS
B-ALL BCR analysis and identiﬁcation of clonal sequences
Longitudinal samples (n= 56) from 15 B-ALL patients taken over
the course of therapy were analyzed for the presence of residual
leukemia by qPCR for transcript levels of fusion genes (six patients,
treated as per UKALL XI protocol) or by % BM blasts (nine patients,
treated as per UKALL2003 protocol). The samples were studied by
analysis of BCR sequencing repertoires and mining of leukemia-
speciﬁc BCR sequences derived from RNA (UKALL2003 samples) or
DNA (UKALL XI samples) (Table 1). The ‘primary’ sample for each
patient, deﬁned as the one with the highest leukemic load, which
was the diagnostic (pre-treatment) sample for all patients except
1703 (567 day relapse sample used) and patient 859 (undergoing
therapy on day 0), was used to identify unique V(D)J sequences
associated with the B-ALL clone(s) (Supplementary Table S1).
Additionally, BCR sequencing was performed on PB from 18 healthy
individuals aged 20–75 years. After ﬁltering, network analysis8 was
performed on BCR sequencing data verifying clonality in all B-ALL
primary diagnostic samples (largest cluster sizes of 5.7–83.64% of
the total BCR repertoire) and the day 567 sample from patient 1703
(largest cluster 3.83%) (Supplementary Table S1). By comparison,
the largest clusters from the healthy individuals averaged 0.60%
(standard deviation of 0.64%, range 0.14–2.577%, Supplementary
Table S2). High reproducibility was observed between the network
structures of two independent PCR ampliﬁcation and sequencing
runs (Supplementary Figure S1).
Using our bespoke computational pipeline (MRDARCY—see
Materials and methods), we identiﬁed B-ALL clonotypic BCRs in
the diagnostic sample and searched diluted or serial patient
samples for identical or related BCRs, allowing for a set number of
base-pair (bp) mismatches (⩽8 bp in this study). MRDARCY was used
to identify clonotypic sequences (clusters representing ⩾ 2.5% of
the entire repertoire, above the 95th percentile of the healthy
range) in the primary samples from six patients treated on the
UKALL2003 protocol and to determine the percentage of matching
BCR sequences in longitudinal RNA samples, also studied for
MRD using fusion gene qPCR. BCR sequencing concurred closely
with qPCR transcript levels (red/green versus blue lines, Figure 1a),
demonstrating strong correlations between the percentage
of clonotypic B-ALL BCRs and qPCR T/C ratios (R2 values40.87,
Supplementary Table S3), while B-ALL clonotypic BCR sequences
were detected in all qPCR-positive samples. Detection of very
low-level B-ALL sequences in some qPCR-negative samples was
reproducible in replicates of the same sample, with the exception of
one sample (Supplementary Table S4, patient 1611, day 19 sample),
from which clonotypic sequences were detected at low frequency
(0.0656%) in only one of two repeats in keeping with stochastic ‘loss’
of a rare variant.8,25–27 Likewise, the percentage of matching BCR
sequences in DNA samples (UKALL XI) correlated with the % blasts
in PB (Figure 1b). Notably, we detected clonotypic sequences in 6 of
10 patients at day 28, where blasts were not detected (o1%).
Therefore, our results show that BCR sequencing is highly sensitive
as a method for MRD detection and at least as good as fusion
gene qPCR.
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Sensitivity for detection of B-ALL clonotypic BCRs
To quantify the sensitivity of BCR sequencing, we performed
a titration experiment using serial 10-fold dilutions of a known
clonal B-ALL RNA sample (1592_A) into healthy PB RNA. With
31.41% of all BCR sequences in the undiluted sample related
to the leukemic cluster, ALL clonotypic BCRs were detected in
dilutions as low as 1 in 107 healthy PB RNA molecules (Figures 1c
and d). Notably, clonotypic BCR sequences from any of the B-ALLs
studied were present by chance only at a rate of 1 in 2 720 172
unique BCR sequences from 8 healthy blood samples ampliﬁed
in the same way (Supplementary Table S5). Sensitivity was further
increased 13.57× when the single primer (from the 6-primer
multiplex set) that best ampliﬁed the leukemic BCRs was used
(Figure 1d, Supplementary Table S6), suggesting that a semi-bespoke
approach could make this an even more powerful MRD tool. Similarly
for DNA, previous studies have demonstrated detection of clonotypic
sequences down to at least 1:10 000 dilution.28
BCR RNA expression levels in mature B cells are higher than those
in pre-B-cells or immature B cells,29 including B-ALL cells, and this
could lead to underestimation of the fraction of malignant B cells in
a sample. We have previously shown that there is a strong linear
correlation in the frequencies of functional BCRs between RNA
and DNA from the same sample.27 Here, by studying three patients
with both DNA and RNA available from the same B-ALL sample,
we ﬁnd that DNA-ampliﬁed B-ALL BCR sequences represented
a much higher percentage of total BCR sequences than RNA-derived
ones (Supplementary Figure S2), most likely due to differences
in RNA expression between B-cell subsets and differences in
RNA stability the B-ALL clone compared with their healthy B-cell
counterparts.30,31 Therefore, the RNA BCR repertoire, although very
powerful in detecting low-level MRD, appears to underestimate the
absolute fraction of residual B-ALL cells in a sample. In support of
this, 80% of cells in the day 567 cerebrospinal ﬂuid (CSF) sample
from patient 1703 were leukemic blasts (CD10+, CD19+, CD45low/−),
while RNA-derived clonotypic B-ALL sequences represented only
3.38% of all BCR sequences (Supplementary Table S7). Therefore,
the use of DNA has the potential to further increase the sensitivity of
BCR repertoire analysis for MRD detection and to provide a better
estimate of leukemic cell numbers as a percentage of total cells.
Nevertheless, both nucleotide sources captured in detail the clonal
architecture of B-ALL clones in each patient.
Analysis of relapse cases: multi-clonal B-ALL from secondary
rearrangements
Biclonal and multi-clonal ALL cases have been detected
in previous studies,32,33 while recent work has shown that
aberrant activity of recombination-activating genes promotes
genomic rearrangements critical to B-ALL pathogenesis.34,35 This
raises the possibility that increased recombination-activating
gene activity may also generate secondary IgHV rearrangements,
such as V-gene replacement, within the B-ALL clone. As IgHD-J
combinations (including junctional regions), known as ‘stem
sequences’ and are stable in instances of secondary rearrange-
ments (Figure 2a),23 we developed a computational approach to
detect B-ALL stem sequences with different IgVH gene usages in
high-throughput sequencing data (Figure 2 and Supplementary
Figure S3). By comparing the frequencies of these stem sequences
in healthy individuals, we account for false-positive detection
rates for each stem sequence (that is, the chance that the same
stem sequence can be generated by chance in independent B
cells). We report that secondary rearrangements are very common
in B-ALL, with an average of 32.52 different IgHV genes combined
with the stem sequence per B-ALL (range 9–59 IgHV genes:
above 99th percentile for healthy individuals; Supplementary
Figure S3 and Supplementary Spreadsheet 1). By determining
the frequency of each stem sequence in unrelated B-ALL patients,
our false detection rate was 9.245 × 10− 6. While it is possible
that these secondary rearrangements may represent pre-leukemic
remnants of clonal diversiﬁcation, examples of cases where the
clones are clearly part of the leukemia were identiﬁed in patients
859, E and F, in which large subclones exhibited identical IgHD-J,
but different V genes (Figure 2).
The two largest clusters in patient 859 (day 0) corresponded
to different IgHV gene rearrangements (IGHV4–34 vs IGHV1–2), but
identical junction and IgHD-J region (55 bp, including 3 bp of non-
template additions) (Figures 2c–e, red and green clusters
respectively), thus consistent with a secondary rearrangement.
These clusters displayed similar properties, including mean
mutational distance from the dominant sequence in each cluster
(2.281 bp and 2.135 bp respectively, Supplementary Table S8). The
cluster 2 IGHV gene (IGHV1–2) was closer to the IGHD/J gene locus
than the gene in cluster 1 (IGHV4–34), and so cluster 1 would have
been a later secondary rearrangement. Interestingly, even though
Table 1. B-ALL patient sample information
Patient ID Fusion gene and
other genetic abnormality
BCR sequence pattern
in diagnostic sample
BCR sequence pattern
in relapse or MRD sample
Disease status BCR sequencing
template
527a E2A-PBX1 Monoclonal expansion Original clone (low level) No relapse RNA
859a ETV6-RUNX1 Biclonal expansionb
(with secondary rearrangements)
Original clone (low level) No relapse RNA
1592a E2A-PBX1 Monoclonal expansion Non-clonal No relapse RNA
1611a E2A-PBX1 Monoclonal expansion Non-clonal No relapse RNAc
1703a ETV6-RUNX1 Monoclonal expansionb Monoclonal expansion (novel clone) CNS relapse
(+ low-level BM)
RNAc
3243a BCR-ABL Monoclonal expansion Non-clonal No relapse RNA
Patient Ad ETV6-RUNX1 Monoclonal expansion Monoclonal expansion (diagnostic clone) BM relapse DNA
Patient Bd Additional RUNX1 Biclonal expansion Monoclonal expansion (of one of diagnostic
clones)
BM relapse DNA
Patient Cd ETV6-RUNX1 Biclonal expansione Biclonal expansion (two diagnostic clones)e BM relapse DNA
Patient Dd TCF3 rearrangement Monoclonal expansion Monoclonal expansion (diagnostic clone) BM relapse DNA
Patient Ed ETV6-RUNX1 Biclonal expansion Monoclonal expansion (diagnostic clone) BM relapse DNA
Patient Fd ETV6-RUNX1 Monoclonal expansion Biclonal expansion (with diagnostic clones) Combined relapse DNA
Patient Gd ETV6-RUNX1; -X;
abn. Chr 3,4,7,12,15
Biclonal expansion Monoclonal expansion (novel clone) Combined relapse DNA
Patient Hd ETV6-RUNX1, loss of one
CDKN2A and one MLL signal
Polyclonal expansion Non-clonal CNS only relapse DNA
Patient Id Bi-allelic CDKN2A deletion Polyclonal expansion Monoclonal expansion (of one of diagnostic
clones)
BM relapse
(+low-level CNS)
DNA
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BCR, B-cell receptor; BM, bone marrow; CNS, central nervous system; MRD, minimal residual disease.
aTreated under the UKALL XI protocol.55 bThe 'diagnostic' samples from patients 859 and 1703 were taken after treatment had commenced. cDNA samples
were also available from these samples (see Supplementary Figure S2). dTreated under the UKALL2003 protocol.55 eLikely to represent bi-allelic VDJ
rearrangements in the transformed B cell.
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Figure 1. BCR sequencing: evaluation of sensitivity and detection of B-ALL clones. (a) qPCR target/control (T/C) transcript ratios (blue) and
percentages of RNA-derived clonotypic B-ALL BCR reads over time for each patient (red for largest cluster and green for second largest cluster,
where present). The blue axes (right of each plot) refer to the T/C qPCR transcript ratio levels and the red axes (left) to the percentage of
sequences in the corresponding clusters (log2 scales). Blue and red bars under each plot indicate time points that are positive for qPCR
transcripts and B-ALL BCR reads, respectively. The initial sample for patient 1703 was taken 2 weeks after starting treatment, hence the low
levels of qPCR and clonotypic BCR positivity at time 0. BM, bone marrow; PB, peripheral blood; CSF, cerebrospinal ﬂuid sample. (b) Variation of
percentages from nine B-ALL patients of BM blasts (top panels) and percentages of DNA-derived clonotypic B-ALL BCR reads over time
(bottom panels, different colored lines are used for each individual clone larger than 2.50% of the total BCR repertoire at any of the indicated
time points). Percentage of sequences in the corresponding clusters is plotted in a square scale to highlight lower frequency observations.
Time points A, B and C refer to diagnosis, day 28 and relapse for each patient, and missing samples are indicated by white squares (patient F,
time B). The gray-shaded area shows the maximum cluster sizes for healthy patients (mean± 2s.d.). Patients are grouped by clinical relapse
type, with BM relapse patients in the green box, combined relapse in the orange box and CNS only/predominant relapse in the blue box. (c, d)
RNA from a B-ALL patient sample was mixed with RNA from healthy peripheral blood mononuclear cells (PBMCs) at different ratios. BCR
sequencing was performed using the full set of multiplex primers or the single primer with the best alignment to the malignant B-ALL BCR
sequence (IgHV-speciﬁc primer), each yielding an average of 125 642 ﬁltered BCR sequences (range of 18 970–294 354). (c) Network diagrams
showing sequential dilution of B-ALL into healthy blood RNA using the multiplex primers, where clusters within 8 bp sequence similarity to
the B-ALL cluster are marked in red and all others in blue. (d) Percentages of BCR sequences corresponding to the B-ALL BCR population at
each dilution using multiplex primers (dark-green) and IgHV-speciﬁc primer (dark-red). Overlaid is the percentage in the largest BCR cluster
(irrespective of relationship to B-ALL) for multiplex primers (light-green) and IgHV-speciﬁc primer (light-red).
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cluster 2 became undetectable from day 84 (Figure 1), cluster 1
was never fully eradicated over 1241 days, suggesting that cells
with this BCR sequence were differentially affected by therapy.
Likewise, the dominant clone in the original patient E B-ALL
sample (Figure 1b, red line) was different from the largest clone
identiﬁed at ﬁrst and second relapses (Figure 1b, purple line) more
than 7.4 years later. The identical 57-bp region spanning the IgHD-
IgHJ region including 10bp of non-template addition between the
IgHV and IgHD genes (Figure 2f, Supplementary Table S9) conﬁrms
that B-ALL relapse arose from a minor subclone of the original
disease. Interestingly, the dominant clone at original diagnosis
was small at time A (0.145%), while the dominant clone at
time A was small at the time of original diagnosis (0.129%)
(Figure 1b). A third subclone in this patient also related by
secondary rearrangement (turquoise line, IGHV2-70-IGHD2-2-
IGHJ4, Figure 1b) was present at low frequency at diagnosis
(0.00367%) and became the second most dominant at time A
(3.491%), but is lost thereafter. Together, these data show that
subclones related by secondary rearrangement can respond
differently to therapy, despite being closely related.
Patient F also shows the presence of a single dominant clone
(80.6%) at diagnosis (time A, Figure 2), while relapse shows two
clones including the original clone (55.9%) and a novel clone
(33.0%). These clones appear to be related by secondary
rearrangement, with identical 84 bp region spanning the IgHD-
IgHJ and 13 bp non-template region (Figure 2g), suggesting clonal
evolution of the leukemia. Therefore, BCR sequencing can detect
multiple disease subclones generated through genomic diversiﬁ-
cation and potentially even rare cases of two independent B-cell
malignancies,8,36 irrespective of their composition of driver
mutations.
An additional consideration when BCR sequencing from DNA,
rather than RNA, is that in some B cells initial BCR rearrangements
are defective and followed by rearrangement of the second BCR
(IgH) allele,37 something seen commonly in B-ALL clones.38 B-ALLs
arising from such B cells would thus mimic the presence of two
independent leukemias when DNA is used to amplify/sequence
BCRs. However, bi-allelically rearranged B-ALLs should exhibit a
strong correlation between sequencing frequencies of the two
rearranged BCRs, whereas BCRs from independent clones would
diverge over time. A bi-allelic rearrangement is likely to have
occurred in the B-ALL from patient C (Table 1) for which only a
single cytogenetic abnormality (ETV6-RUNX1), but two clonal BCR
rearrangements were present and highly co-correlated through
the disease course (R2 value = 0.988).
Association of relapse patterns with BCR repertoires
Differences in B-cell repertoires were associated with different
patterns and sites of relapse. For all cases without cytogenetic
evolution (9/10 of relapse patients), relapse was associated with
re-emergence of B-ALL clones present at diagnosis (including
clones related by secondary rearrangements). Patients A–E
exhibited relapse in the BM only, where the dominant BCR
clone(s) at diagnosis (time A) re-emerged at relapse (time C)
(Figure 1b). Patient F shows the re-emergence of the original
diagnostic clone at relapse as well as a novel clone related by
secondary rearrangement as described earlier. The single case
where cytogenetic clonal evolution occurred between diagnosis
and relapse (patient G, additional gain of chromosome 21)
corresponded to the emergence of a novel B-ALL BCR clone at
relapse. Here, the original diagnostic B-ALL clonal BCR sequences
were not detected at relapse. For patients 1703 and H, with CNS
relapse (no blasts in BM), there were only low-level B-ALL BCRs
detectable in BM DNA. In particular, only 0.353% of B-ALL BCRs
was detected in BM DNA from patient H (Figure 1b) and for
patient 1703 (RNA sample) the CSF was found to contain a
signiﬁcantly higher proportion of B-ALL BCRs compared with the
BM (Figure 1a). These ﬁndings suggest that changes in BCR
sequences may signify differences in biological behavior and that
studying interim CSF samples for MRD may be of clinical value.
B-ALL clonal complexity is signiﬁcantly retained between
diagnosis and relapse
Despite the fact that adenosine-induced deaminase (AID) expres-
sion is detected only in some B-ALLs,39–42 the accumulation of
low-level AID- or non-AID-mediated BCR mutations can result in
clonal diversiﬁcation.43 Indeed, the mutations within these clusters
are enriched within the CDR1-3 regions compared with FWR1-3
regions (Supplementary Figure S4) and in AID mutational motifs
(Supplementary Table S10), suggestive of AID activity.44–46 These
mutations can be used to infer the hierarchical structure and
extent of BCR diversiﬁcation from a leukemia-initiating B-cell to
bulk leukemia. To investigate the effect of treatment on the
population structure of B-ALL, we studied diagnostic-relapse pairs
exhibiting related BCRs, thus permitting sequence comparisons
(patients A, C–F). B-ALL clonal sequences from diagnosis and
relapse of each patient differing by ⩽ 8bp were aligned using
Mafft17 and maximum parsimony trees ﬁtted using Paup*.18 To
reduce the risk of including sequences with errors, only BCRs that
were observed at least twice were included (Figures 3a–f). The
same analysis was performed on BM and CSF relapse samples
from patient 1703 between day 0 (RNA and DNA data sets) and
day 567 relapse (Figure 3g). The star-like structure of each tree
Figure 2. Secondary IgHV rearrangements in B-ALL subclones. (a) Schematic representation of different mechanisms of secondary IgHV
rearrangements. (i) Independent IgHV rearrangements: After the D-J rearrangement, an early B cell divides and the resulting cells undergo
independent IgHV rearrangements, while retaining a common IgHD-J stem sequence. (ii) IgHV replacement: an upstream IgHV gene is
rearranged onto a pre-existing D-J rearrangement. (b) High-throughput detection of secondary rearrangements in B-ALL patient samples for
(i) patient 859, (ii) patient E and (iii) patient F. The percentages of BCR sequences containing the stem sequences from the major clones in each
patient were identiﬁed in serial time points (encompassing the IgHD-IgHJ region and non-template additions up to 3 bp 3’ to the end of the
IgHV gene, Supplementary Table S8). Different IgHV gene usages are plotted in different colors, and the highest three observed IgHV genes
indicated above the plots. The gray lines indicate the top 99th percentile frequency of each stem sequence in 18 healthy individuals (0% for
i–iii). (c) Network diagram for B-ALL patient 859 at day 0, with vertices within the largest cluster (cluster 1) in red, vertices within the second
largest cluster (cluster 2) in green and all other vertices in blue. (d) BCR sequence alignment of the dominant sequences from the two
dominant clusters in patient 859, cluster 1 and cluster 2 representing 2.81 and 2.89% of BCRs, respectively. The cluster 1 and 2 sequences were
aligned to each other, and the positions of differences between sequences are indicated by the colored boxes in the corresponding positions
in the middle row, using red for mismatches, green for gaps in cluster 1 BCR and blue for gaps in cluster 2 BCR. The cluster 1 and 2 sequences
were 100% identical to the germline genes of (IgHV4-34-IgHD4-11-IgHJ6) and (IgHV1-2-IgHD4-11-IgHJ6), respectively, where the red, blue and
green boxes for IgHV, D and J genes mark the gene boundaries respectively. (e–g) Alignments of the two largest BCR sequence clusters for
patient 859 (e), patient E (f) and patient F (g). The alignments with the reference IgHV (highlighted in red), IgHD (highlighted in yellow) and
IgHJ (highlighted in green) genes are indicated with dashes (-) denoting alignment gaps. The regions of the BCR sequence that are identical
between the two clusters are highlighted in the gray boxes.
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reveals that the original B-ALL clone for each of these patients
emerged from a single common ancestor,47 represented by the
central BCR, which was in all cases the most frequently observed
BCRs in both the diagnostic and relapse samples. Strikingly,
beyond the central BCR, there was also high sequence overlap
between the entire diagnostic and relapse sample BCR repertoires
(478% of unique BCRs within each clone for patients A–F and
13.6% for patient 1703, whose day 0 sample was collected after
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initial anti-leukemic therapy), even at distances of47 nucleotides
from the central BCR for each patient (Figure 3 and
Supplementary Table S11). The strong linear correlations between
the B-ALL BCR frequencies at diagnosis and relapse (R2
values40.95, Figure 3) indicate that much of the population
structure of the B-ALL clones is retained throughout the course of
therapy and while the disease is in clinical remission (Figure 4).
The hypothesis that a population of B-ALL clones with distinct
BCR sequences persisted through therapy and re-emerged at
relapse (Figure 4) can be statistically tested by calculating the
probability that an overlap of BCR sequences between diagnosis
and relapse samples can happen by chance. The hypergeometric
test showed that the probability of observing equal or greater
BCR sequence overlap between diagnosis and relapse was
signiﬁcantly higher than expected by chance for all pairs tested
(P-valueso10− 15, Supplementary Table S11). For example, patient
A had two unique BCRs with nine nucleotide differences from the
central BCR at diagnosis, of which one was resampled at relapse 3
years later. The probability of this occurring by chance if relapse
had emerged from a single BCR is negligible. This was conﬁrmed
by sequencing diagnostic and relapse samples from a subset of
the patients (A, C, D and E) on separate PacBio sequencing runs,
and sequences were matched to the B-ALL clones. Indeed, even at
a low sequencing depth, overlap of non-central BCR sequences
was observed between diagnosis and relapse (Supplementary
Table S12 and Supplementary Figure S5), conﬁrming that this
observation is independent of sequencing platform. To account
for any mutational biases generated through PCR and sequencing,
the baseline observed probabilities of overlap of mutations
in independent V-(D)-J recombination events were used to
compare the diagnosis-relapse samples. There were signiﬁcantly
higher numbers of overlapping mutations between diagnosis and
relapse samples than were observed between independent clonal
rearrangements (P-values o10−50, Supplementary Table S13).
The potential of overlap originating from Illumina multiplex
identiﬁcation (MID) tag mixing was eliminated as samples from
each time point and each technical repeat were sequenced
on different MiSeq runs. PCR error can be distinguished from true
BCR subclonal mutations as they are subjected to different
mutational processes, thus exhibiting different mutational proﬁles.
The relative frequencies of each mutation within mutational
triplets were compared between B-ALL clonal sequences and
control genes (human β-globin/GAPDH) and showed that 29/96
mutational signatures were signiﬁcantly different (Po0.005,
Figure 3. Phylogenetic analysis of paired diagnosis-relapse B-ALL samples. (a) The correlation of B-ALL BCR frequencies between diagnostic
and relapse samples (as a percentage of reads in the corresponding clone) observed in (from left to right) DNA samples for patient A cluster 1,
patient C cluster 1, patient C cluster 2, patient D cluster 1, patient E cluster 1 and patient F cluster 1 and for patient 1705 cluster 1 (day 0
(combined RNA and DNA sequencing data sets) against relapse (day 567, RNA sequencing data set)). Point colors are blue if the BCR was
present only in the diagnostic sample, red if present in both the diagnostic and relapse samples, and green if present only in the relapse
sample. Cube-root scales used to highlight the low-frequency BCRs, and presented with the corresponding R2 values. (b) Unrooted maximum
parsimony trees showing the relationships between sequences observed in diagnostic and relapse DNA samples for (i) patient D cluster 1 and
(ii) patient F cluster 1. Branch lengths are proportional to the number of varying bases (evolutionary distance). Bootstrapping was performed
to evaluate the reproducibility of the trees suggesting strong support for the majority of the branches (470% certainty for branches). Tips
represent BCR sequences with point sizes correlating with the proportion of reads for a particular sequence (for display purposes this is not
the case for the central cluster, whose size is ﬁxed). The tip colors are blue if the BCR was present only in the diagnostic sample, red if present
in both the diagnostic and relapse samples and green if present only in the relapse sample. *The day 0 sample for patient 1703 was taken after
chemotherapy had started, hence the depletion of the diagnostic repertoire reﬂected in the dominance of green tips.
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Supplementary Figure S6). After accounting for multiple testing
(Bonferroni correction), there were no comparisons with signiﬁcantly
higher overlap between mismatched sites than expected by chance
(P-valueso0.005, Supplementary Figure S7 and Supplementary
Table S14). This suggests that PCR/sequencing error is primarily
a random process and that there were no common error-prone
sites in the BCR sequence during these steps. This supports the
notion that variation in these clusters reﬂects true diversity of B-ALL
samples.
Although in all seven cases analyzed, a single large clone
represented the great majority of BCR sequences, multiple B-ALL
cell clones with distinct BCRs also re-emerged at relapse. B-ALL
relapse is frequently associated with the acquisition of drug resistance
mutations in genes such as CREBBP,48 NT5C2,49,50 SETD251 and
others52 so we propose that the opportunity/likelihood of acquisition
of such mutations increases with the number of residual B-ALL cells
during remission, which is in turn determined by partial chemore-
sistance and/or inadequate therapy (Figure 4).
DISCUSSION
We describe a technical and analytical approach for quantitative
detection of MRD and characterization of B-ALL clonal architecture
using BCR sequencing. Given a priori knowledge of the clonotypic
BCR sequence, MRD detection was at least as sensitive as with
qPCR-based methods, while BCR sequencing is universally applic-
able to all cases irrespective of their cargo of oncogenic mutations.
BCR sequencing can detect multiple disease subclones such as
those in which B-ALL has undergone secondary rearrangements
or cases with two independent B-cell malignancies,8,36 and in this
study we show an unexpectedly high incidence of secondary
rearrangements in all cases studied. Importantly, multiple clinically
signiﬁcant clones carrying distinct IgHV-DJ rearrangements were
identiﬁed in several B-ALLs. Using the BCR stem regions (IgHD-J)
as molecular barcodes, we reveal the disparate dynamics of
cellular clones suggesting differential responses to therapy, different
growth rates within different anatomical sites and emergence
of novel clones at relapse corresponding with the cytogenetic
Figure 4. Proposed signiﬁcance of the overlap between diagnostic and relapse BCR repertoires. Initial intensive therapy reduces the number
of B-ALL B cells in a patient to MRD levels and then to undetectable levels before the start of maintenance therapy. During maintenance
therapy, the likelihood of acquisition of resistance mutations is proportional to the number of residual clonogenic B-ALL cells. In the depicted
example, multiple independent clonogenic cells survive intensive therapy because of relative inherent chemoresistance (or inadequate
dosing) and persist throughout maintenance therapy. This increases the likelihood of and leads to the acquisition of a resistance mutation in
one of these cells. Nevertheless, B-ALL remains suppressed and undetectable while on maintenance therapy only to relapse after treatment is
completed (relapse while on still on treatment is evidently also possible through the same mechanism, but less common). While the main
B-ALL clone dominates both the diagnosis and the relapse BCR repertoires, smaller related clones are detected at both these time points
providing a surrogate for the inherent chemoresistance of the particular B-ALL or inadequate dosing for the individual patient. *No disease
detectable by light microscopy.
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evolution. Given the abundance of derivative B-ALL clones, and their
independent growth trajectories in response to treatment, monitor-
ing all emerging and growing clones can be of clinical importance
and can be achieved using BCR sequencing.
As with somatic mutations elsewhere in the genome,53
mutations in the BCR reﬂect B-ALL clonal diversiﬁcation and can
be used to infer phylogenetic relationships between subclones.
Unlike subclones characterized by different oncogene mutations,
those deﬁned by differences in BCR sequence do not necessarily
display distinct biological behaviors but do capture the evolution
and phylogenetic history of the clone. In keeping with the
accepted paradigm of cancer evolution, the star-like structures of
B-ALL BCR repertoires indicate that each leukemia emerged from
a single common B-cell ancestor or stem cell. Importantly, we go
on to show that B-cell repertoires at diagnosis and relapse
overlapped signiﬁcantly in all seven cases studied here, indicating
that much of the population structure of B-ALL is retained during
remission. Nevertheless, a single dominant clone/BCR sequence
was always identiﬁed that was identical to the dominant clone
at diagnosis, with other clones remaining much smaller (Figure 4).
Previous studies have shown that B-ALL relapse is often driven
by relapse-speciﬁc chemoresistance mutations in loci such as the
NT5C2 nucleotidase gene,49,50 or mutations in genes like SETD2,
CREBBP and others, which can be present at diagnosis or gained at
relapse.48,51 We propose that the persistence of small B-ALL clones,
deﬁned by their unique BCR sequence, is a surrogate for partial
inherent chemoresistance and/or inadequate initial therapy. This in
turn increases the likelihood of acquisition of bona ﬁde chemore-
sistance mutations in at least one of the surviving cells, whose
progeny then go on to dominate relapse (Figure 4). This explains
recent observations that subclones without identiﬁable resistance
mutations survive initial chemotherapy and acquire resistance
mutations in their descendants.52 Also, it explains why the level of
MRD at early stages of treatment (for example, day 19) is a good
predictor of long-term survival13,54 and emphasizes the importance
of residual disease as the conduit for chemoresistance-driven
relapse. In this context, the higher sensitivity of our method could
be exploited to further enhance the ability of early-stage MRD levels
to predict long-term prognosis, by differentiating patients with and
without very low-level MRD with greater accuracy and at later
stages of initial therapy (we detected MRD on day 28 in six of eight
cases who went on to relapse).
In summary, we show the broad applicability and exquisite
sensitivity of our BCR sequencing and analysis method for MRD
monitoring of B-ALL and use this method to reveal clinically
relevant features of B-ALL clonal dynamics, including the extent of
clonal diversiﬁcation through both hypermutation and secondary
rearrangement, and the ﬁrst demonstration of the persistence
of multiple small B-ALL clones throughout therapy in patients
who went on to relapse. This ﬁnding puts the spotlight on early
aggressive cytoreduction or change in therapy as a means for
decreasing the likelihood of chemoresistant relapse.
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